Thursday, May 8, 2014

New Developments in Medical Management for mCRPC By: Dr. Martin Gleave, Canada

Learn from our expert, Dr. Martin Gleave, as he reviews the problem of castration and acquired treatment resistance in prostate cancer, theevolving treatment landscape in metastatic castration-resistant prostate cancer (mCRPC), provides an update on current CRPC mechanisms and novel targets, including implications for the future. 

There’s been a vast improvement in our understanding of the biology and mechanisms that drive treatment resistance in castrate-resistant prostate cancer. We are identifying novel pathways and targets that we can then manipulate. While the androgen receptor remains the key driver, there are others and we have to figure out how to best to combine them in a context-dependent way….” – Dr. Martin Gleave



Post a Comment

Twitter Delicious Facebook Digg Stumbleupon Favorites More

Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review